Actinium-225 Dotate

N/A

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameActinium-225 Dotate
Drug Alias NameRYZ-101225Ac-DOTATATE[225Ac]Ac-DOTATATE
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionSomatostatin receptor 2 binders
TargetsSomatostatin receptor 2
Therapy Area/IndicationsMetastatic breast cancerGastroenteropancreatic neuroendocrine tumorSmall Cell Lung Carcinoma +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesRayzeBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Cancer HospitalRayzeBio IncBeijing Xiantong International Technology Co Ltd
Inactive CompaniesJules Bordet Institute
Active IndicationsMetastatic breast cancerGastroenteropancreatic neuroendocrine tumorSmall Cell Lung Carcinoma +[8] 
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A